Marker Therapeutics, Inc. (NASDAQ:MRKR) Short Interest Down 14.3% in March

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the recipient of a large drop in short interest in the month of March. As of March 31st, there was short interest totaling 512,684 shares, a drop of 14.3% from the March 15th total of 598,274 shares. Based on an average daily volume of 114,314 shares, the short-interest ratio is presently 4.5 days. Approximately 3.3% of the company’s shares are sold short.

Marker Therapeutics Price Performance

Marker Therapeutics stock traded up $0.09 during mid-day trading on Friday, reaching $1.70. The stock had a trading volume of 79,651 shares, compared to its average volume of 279,514. Marker Therapeutics has a one year low of $0.81 and a one year high of $4.07. The company has a 50-day moving average price of $1.44 and a two-hundred day moving average price of $1.37. The company has a market capitalization of $28.34 million, a price-to-earnings ratio of -2.00 and a beta of 1.47.

Marker Therapeutics (NASDAQ:MRKR) last issued its earnings results on Wednesday, March 18th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.17. The business had revenue of $1.10 million during the quarter, compared to analysts’ expectations of $0.68 million. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 80.86%. On average, equities research analysts anticipate that Marker Therapeutics will post -0.65 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Marker Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MRKR. Virtu Financial LLC bought a new stake in shares of Marker Therapeutics in the 3rd quarter worth $25,000. Two Sigma Investments LP purchased a new stake in shares of Marker Therapeutics during the third quarter valued at $33,000. Jane Street Group LLC bought a new stake in Marker Therapeutics in the 2nd quarter worth about $33,000. Boyer Financial Services Inc. bought a new stake in Marker Therapeutics in the 4th quarter worth about $57,000. Finally, XTX Topco Ltd lifted its stake in Marker Therapeutics by 166.6% during the 4th quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock valued at $86,000 after acquiring an additional 36,269 shares during the period. 22.39% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. Wall Street Zen upgraded shares of Marker Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 3rd. Zacks Research cut shares of Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Marker Therapeutics in a research report on Friday, March 27th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Marker Therapeutics has a consensus rating of “Hold” and an average price target of $10.00.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.